Patents Examined by Barbara P. Badio
  • Compositions and formulations for treatment of malignancies
    Patent number: 11559500
    Abstract: The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: January 24, 2023
    Assignee: NEUGATE PHARMA, LLC
    Inventor: Yvonne Kew
  • Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders
    Patent number: 11542296
    Abstract: Described herein is the chemical structure of neurosteroid derivative compounds, methods of synthesizing the derivatives, and their uses in treating disorders, including those of the central nervous system. These compounds are readily synthesized and have improved pharmaceutical properties, including water solubility, compared to known neurosteroids.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: January 3, 2023
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventor: Doodipala Samba Reddy
  • Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes
    Patent number: 11542227
    Abstract: A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 3, 2023
    Assignee: Texas Tech University System
    Inventors: Susan E. Bergeson, Peter Syapin, Ted W. Reid, Mayank Shashtri, Phat Tran
  • Compounds for the treatment of acute organ injury
    Patent number: 11534425
    Abstract: Disclosed herein are novel compounds and methods for the treatment of acute organ injury, including injuries resulting from ischemic events. The compounds may be used to treat organ including the brain, heart, or kidney, which have injured as a result of events such as stroke, cardiac arrest, traumatic brain injury, hemorrhagic shock, or subarachnoid hemorrhage.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: December 27, 2022
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Travis C. Jackson, Patrick M. Kochanek
  • Fluorinated bile acid derivatives
    Patent number: 11517577
    Abstract: The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: December 6, 2022
    Assignees: NZP UK LIMITED, THE UNIVERSITY OF SOUTHAMPTON
    Inventors: Alexander Charles Weymouth-Wilson, Gemma Packer, Bruno Jan Pol Linclau, Dannielle Kydd-Sinclair, Kimberly Ann Watson
  • Nonracemic mixtures and uses thereof
    Patent number: 11517558
    Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: December 6, 2022
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Cabot Hopkins, Kenneth Stephen Koblan, John R. Snoonian, Harold Scott Wilkinson
  • Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation
    Patent number: 11512107
    Abstract: The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds to treat a disease, such as a brain tumor and, particularly, a glioma.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: November 29, 2022
    Assignee: Trustees of Dartmouth College
    Inventor: Glenn C. Micalizio
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 11498940
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: November 15, 2022
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Robert Jason Herr, Robert Borbo Kargbo
  • Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer
    Patent number: 11484511
    Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 1, 2022
    Assignee: KOREA UNITED PHARM, INC.
    Inventors: Keon Wook Kang, Sung Baek Jeong
  • Treatment for glioblastoma
    Patent number: 11478453
    Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: October 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Lavon Ben Moshe, Tamar Canello Avramovitch
  • Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
    Patent number: 11479577
    Abstract: The present invention relates to compounds which are intermediates in the synthesis of bile acid derivatives with pharmacological activity. The invention relates to compounds of general formula (I): wherein: , R1, R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditions such as liver disease. In addition, the invention relates to a method of synthesizing these intermediates and a method of preparing obeticholic acid and obeticholic acid analogues from the compounds of the invention.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: October 25, 2022
    Assignee: NZP UK Limited
    Inventors: Alexander Weymouth-Wilson, Zofia Komsta, Laura Wallis, Timothy Evans, Ieuan Davies, Carl Otter, Rhys Batchelor
  • Neuroactive steroids and methods of preparation
    Patent number: 11472833
    Abstract: Neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same are disclosed. Also provided are scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone and alfadolone acetate.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 18, 2022
    Assignee: DRAWBRIDGE PHARMACEUTICALS PTY LTD
    Inventors: Ian Edmonds, Edward J. Hessler
  • Therapeutic DNP derivatives and methods using same
    Patent number: 11472764
    Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: October 18, 2022
    Assignee: Yale University
    Inventors: Gerald I. Shulman, David A. Spiegel
  • Aminosterol compositions and methods of using the same for treating schizophrenia
    Patent number: 11464789
    Abstract: The present application relates generally to methods for treating, preventing and/or slowing the onset or progression of schizophrenia and/or a related symptom. The methods comprise administering at least one aminosterol or a pharmaceutically acceptable salt or derivative thereof to a subject in need.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: October 11, 2022
    Assignee: Enterin, Inc.
    Inventors: Denise Barbut, Michael Zasloff
  • Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
    Patent number: 11458146
    Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to inflammation, such as necrotizing enterocolitis, mesenteric ischemia, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, lymphocytic colitis, Celiac disease. Behcet's disease, rheumatoid arthritis, psoriasis, and autoimmune thyroid disease.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: October 4, 2022
    Assignee: Duke University
    Inventors: Eric Benner, Simon Gregory
  • Conducting reactions in leidenfrost-levitated droplets
    Patent number: 11459299
    Abstract: The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 4, 2022
    Assignee: Purdue Research Foundation
    Inventors: Robert Graham Cooks, Christopher Pulliam, Ryan M. Bain
  • Preparation method of vascular leakage blockers with a high yield
    Patent number: 11453698
    Abstract: The present invention relates to a preparation method of a novel vascular leakage blocker with a high yield. The preparation method is easy to react and more productive and economical than the conventional method by using an intermediate that can easily remove impurities generated during the reaction. In addition, the preparation method can produce a novel vascular leakage blocker with a high yield by using a new reagent that has not been previously used in the step of generating an isomer, and is very advantageous in producing a high-quality active pharmaceutical ingredient.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: September 27, 2022
    Assignee: CURACLE CO., LTD.
    Inventors: Koo Hyeon Ahn, Myung-Hwa Kim, Jung-Ln Pyo, Chul Su Baek, Sung Hwan Kim
  • Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
    Patent number: 11440936
    Abstract: This invention relates to methods of stimulating the activity of the human and animal enteric nervous system. The method comprises orally administering an aminoserol, such as squalamine, a naturally occurring aminosterol isolated from Squalus acanthias, or derivatives thereof, to a subject in need.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: September 13, 2022
    Assignee: Enterin, Inc.
    Inventor: Michael Zasloff
  • Pharmaceutical composition comprising gallstone solubilizer for treatment of gallbladder disease
    Patent number: 11400056
    Abstract: The present disclosure relates to a pharmaceutical composition for treating gallbladder disease containing a gallstone-dissolving agent, and more specifically, to a pharmaceutical composition for treating gallbladder disease containing a gallstone-dissolving agent which dissolves gallstone, a cause of the gallbladder disease, and thus has an excellent effect of alleviating or treating any one or more symptoms selected from the group consisting of asymptomatic cholelithiasis, biliary colic, cholecystitis, choledocholithiasis, and biliary pancreatitis.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: August 2, 2022
    Assignee: SurgiNex Co., Ltd.
    Inventors: Say June Kim, Kwan Young Jeong, Ok Hee Kim, Seok Jun Jo, Min Jin Yoo
  • Deuterated compounds and uses thereof
    Patent number: 11401234
    Abstract: An anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumour, are also provided. Additionally, an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumour cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, are additionally provided.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: August 2, 2022
    Assignee: ONCOTHERICS VENTURES LIMITED
    Inventors: Stefan Ogrodzinski, Paul Smith, Stephanie McKeown, Laurence Patterson, Rachel Jane Errington